A double-blind placebo-controlled crossover trial was used to determine the effects of topical ketamine, an N-methyl-D-aspartate (NMDA) receptor antagonist, on the sensory disturbances in 20 patients with complex regional pain syndrome (CRPS). On two occasions separated by at least one week, sensory tests to light touch, pressure, punctate stimulation, light brushing and thermal stimuli were performed in the symptomatic and contralateral limb and on each side of the forehead before and 30 min after 10% ketamine cream was applied to the symptomatic or healthy limb. Venous blood for the plasma estimations of ketamine and norketamine was obtained 1 h after application of the creams. Ketamine applied to the symptomatic limb inhibited allodynia to light brushing and hyperalgesia to punctate stimulation. Systemic effects of the ketamine are unlikely to account for this as the plasma levels were below detectable limits. As touch thresholds were unchanged, NMDA receptors may contribute to the sensory disturbances in CRPS via actions at cutaneous nociceptors. Allodynia and hyperalgesia were detected in the ipsilateral forehead to a range of stimuli (brushing, pressure, punctate stimulation, cold, heat, and warmth). In several patients, ketamine treatment of the symptomatic limb inhibited allodynia to brushing the ipsilateral forehead, suggesting that the mechanism that mediates allodynia in the symptomatic limb contributed to allodynia at more remote sites. The present study shows promise for the use of topical ketamine as opposed to parenteral and oral forms which often result in undesirable side effects. Ó
Introduction
Complex regional pain syndrome (CRPS) can develop after apparently trivial injury and is often associated with widespread sensory disturbances [21, 64, 77] . Unfortunately, the treatment of neuropathic pain states, including CRPS, remains a significant challenge [19] . Moreover, many of the commonly used orally administered drugs can cause significant central side effects such as somnolence and cognitive impairment with loss of patient compliance [30, 33] . A number of topical applications have been tried for neuropathic pain states, targeting peripheral receptor systems and pain mediators, but with mixed success [16, 17, 36, [39] [40] [41] 47, 48, 53, 59, 79, 84, 89, 94, 97] .
Glutamatergic mechanisms are widely involved in excitatory neurotransmission, including nociception [7, 68, 88] . Of particular importance is the involvement of N-methyl-D-aspartate (NMDA) receptors in chronic pain states, including CRPS. As all major groups of glutamate receptor are found on nerve fibres in peripheral tissues [10] , it would appear logical to attempt local peripheral block of NMDA receptors to reduce allodynia in CRPS. The general anaesthetic agent ketamine [18] , and its major metabolite norketamine, have a significant non-competitive blocking action on NMDA receptors [1, 24] . Subanaesthetic dosage of ketamine provides worthwhile analgesia both in acute, postoperative and chronic pain states [4] . Trials of the use of ketamine in the treatment of neuropathic pain states have largely revolved around its intravenous administration [2, 3, 5, 11, [25] [26] [27] 29, 34, 37, 42, [49] [50] [51] 54, 69, 71, 80, 82, 93] [15, 31, 75, 91] and topical application [12, 32, 41, 57, 60, 61, 73, 74, 81, 90] . Several randomised, double-blind, placebo-controlled studies have reported on the reduction of allodynia following intravenous administration of ketamine [7, 25, 28, 29, 65] but literature on the topical use of ketamine is particularly sparse, mostly comprising case studies. To our knowledge, only one group has reported the effects of topical ketamine on pain and hyperalgesia in a double-blind, placebo-controlled trial. In this study neither ketamine 1% nor amitriptyline 2%, either separately or combined, were effective in patients with neuropathic pain, possibly because drug concentrations were suboptimal [60] . 
